Annual Industry Ranking And Forecast
The RNA class of products is becoming more attractive to drug developers and investors. Dealmakers have been busy in 2022.
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.
With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.
In this episode of the In Vivo podcast, David Wild speaks with Petra Jantzer, senior managing director and global life sciences lead at Accenture, about the changing deals landscape. The discussion centers on the shifts in M&A strategies that Jantzer has been seeing among big pharmas and the need for other companies to adapt to a world in which technologies and processes become a key focus of growth.
The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.